Stevanato Group Secures $235.4 Million in Financing

Stevanato Group S.p.A., a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, has secured €200 million ($235.4 million) in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM, intended to support its ongoing capital expenditure projects in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.).

The financing agreements bolster Stevanato Group’s capacity expansion efforts and the scaling of commercial production to support customers’ growing biologics programs. CDP has committed €50 million to enhance the production of pre-filled syringes and set-up future capacity for ready-to-use (RTU) cartridges at Stevanato Group’s Italian plant in Cisterna di Latina. Additionally, BNL BNP Paribas has provided €100 million, and Banco BPM has contributed €50 million, both aimed at scaling pre-filled syringe production at the company’s facilities in North America (Indiana) and Italy, as well as completing the ongoing construction for device manufacturing in Fishers.

“These agreements are an important element to Stevanato Group’s financial strategy, allowing us to capitalize on robust customer demand and support the Company’s long-term growth objectives,” stated Marco Dal Lago, Chief Financial Officer of Stevanato Group. “We are committed to supporting our customers’ biopharmaceutical programs with our unique value proposition of offering integrated solutions across the pharmaceutical value chain, helping to enable our customers to meet and exceed their program objectives.”